The importance of cell culture parameter standardization: an assessment of the robustness of the 2102Ep reference cell line

References

• Kirkeby A, Nolbrant S, Tiklova K, et al. Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for parkinson’s disease. Cell Stem Cell. 2017;20(1):135–148.
   PubMed Web of Science ®Google Scholar
• Sundberg M, Bogetofte H, Lawson T, et al. Improved cell therapy protocols for Parkinson’s disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells. 2013;31(8):1548–1562.
   PubMed Web of Science ®Google Scholar
• Grealish S, Diguet E, Kirkeby A, et al. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson’s disease. Cell Stem Cell. 2014;15(5):653–665.
   PubMed Web of Science ®Google Scholar
• French A, Bravery C, Smith J, et al. Enabling consistency in pluripotent stem Cell-Derived products for research and development and clinical applications through material standards. Stem Cells Transl Med. 2015;4(3):217–223.
   PubMed Web of Science ®Google Scholar
• Carmen J, Burger SR, McCaman M. Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development. Regen Med. 2012;7(1):85–100.
   PubMed Web of Science ®Google Scholar
• Abbasalizadeh S, Baharvand H. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotechnol Adv. 2013;31:1600.
   PubMed Web of Science ®Google Scholar
• Deasy BM, Jankowski RJ, Payne TR, et al. Modeling stem cell population growth: incorporating terms for proliferative heterogeneity. Stem Cells. 2003;21(5):536–545.
   PubMed Web of Science ®Google Scholar
• Salmikangas P, Menezes-Ferreira M, Reischl I, et al. Manufacturing, characterization and control of cell-based medicinal products: challenging paradigms toward commercial use. Regen Med. 2015;10(1):65–78.
   PubMed Web of Science ®Google Scholar
• Lipsitz YY, Timmins NE, Zandstra PW. Quality cell therapy manufacturing by design. Nat Biotechnol. 2016;34(4):393–400.
   PubMed Web of Science ®Google Scholar
• Kusena JW, Thomas RJ, McCall MJ, et al. From protocol to product: ventral midbrain dopaminergic neuron differentiation for the treatment of Parkinson’s disease. Regen Med. 2019;14(11):1057–1069.
   PubMed Web of Science ®Google Scholar
• Vatsan RS, Bross PF, Liu K, et al. Regulation of immunotherapeutic products for cancer and FDA’s role in product development and clinical evaluation. J Immunother Cancer. 2013;1(1):1–5.
   PubMedGoogle Scholar
• Bubela T, McCabe C, Archibald P, et al. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regen Med. 2015;10(7):897–911.
   PubMed Web of Science ®Google Scholar
• Rowley J, Abraham E, Campbell A, et al. Meeting lot-size challenges of manufacturing adherent cells for therapy. Bioprocess Int. 2013;10:16–22.
   Google Scholar
• Bravery CA, Carmen J, Fong T, et al. Potency assay development for cellular therapy products: an ISCT* review of the requirements and experiences in the industry. Cytotherapy. 2013;15(1):9–19.e9.
   PubMed Web of Science ®Google Scholar
• U.S. Department of health and human services, food and drug administration C for BE and R. Draft guidance for industry: potency tests for cellular and gene therapy products. Biotechnol Law Rep. 2011;27:568–577.
   Google Scholar
• Huang J, Kaul G, Cai C, et al. Quality by design case study: an integrated multivariate approach to drug product and process development. Int J Pharm. 2009;382(1–2):23–32.
   PubMed Web of Science ®Google Scholar
• Williams DJ, Archer R, Archibald P, et al. Comparability: manufacturing, characterization and controls, report of a UK regenerative medicine platform pluripotent stem cell platform workshop, Trinity Hall, Cambridge, 14-15 September 2015. Regen Med. 2016;11(5):483–492.
   PubMed Web of Science ®Google Scholar
• Brindley DA, French AL, Baptista R, et al. Cell therapy bioprocessing technologies and indicators of technological convergence. Bioprocess Int. 2014;12:14–21.
   Google Scholar
• Salmikangas P. Dossier Requirements for ATMPs: scientific requirements for cell therapy and tissue engineered products - Quality Aspects [Internet]. Workshop on Advanced Therapy Medicinal Products, European Medicines Agency (EMA) London; 2009. //www.ema.europa.eu/en/documents/presentation/quality-requirements-cell-based-medicinal-products-paula-salmikangas_en.pdf
   Google Scholar
• European Medicines Agency. Guideline on human cell-based medicinal products. Doc Ref EMEA/CHMP 2008; EMA:EMEA/CHMP/410869/2006.
   Google Scholar
• Doi D, Samata B, Katsukawa M, et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports. 2014;2(3):337–350.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. ICH Topic Q5D quality of biotechnological products : derivation and characterisation of cell substrates used for production of biotechnological/biological products. 1997.
   Google Scholar
• Jones BS, Lamb LS, Goldman F, et al. Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol. 2014;5:254.
   PubMedGoogle Scholar
• Yagyu S, Hoyos V, Del Bufalo F, et al. An inducible caspase-9 suicide gene to improve the safety of therapy using human induced pluripotent stem cells. Mol Ther. 2015;23:1475–1485.
   PubMed Web of Science ®Google Scholar
• Josephson R, Ording CJ, Liu Y, et al. Qualification of embryonal carcinoma 2102Ep as a reference for human embryonic stem cell research. Stem Cells. 2007;25:437–446.
   PubMed Web of Science ®Google Scholar
• Andrews PW. Human embryonal carcinoma cells in culture do not synthesize fibronectin until they differentiate. Int J Cancer. 1982;30:567–571.
   PubMed Web of Science ®Google Scholar
• Pamies D, Bal-Price A, Simeonov A, et al. Good cell culture practice for stem cells & stem-cell-derived models. Altex. 2017;34(1)95–132.
   PubMedGoogle Scholar
• Allegrucci C, Young LE. Differences between human embryonic stem cell lines. Hum Reprod Update. 2007;13(2):103–120.
   PubMed Web of Science ®Google Scholar
• Geraghty RJ, Capes-Davis A, Davis JM, et al. Guidelines for the use of cell lines in biomedical research. Br J Cancer. 2014;111(6):1021–1046.
   PubMed Web of Science ®Google Scholar
• Plaia TW, Josephson R, Liu Y, et al. Characterization of a new NIH-registered variant human embryonic stem cell line, BG01V: a tool for human embryonic stem cell research. Stem Cells. 2006;24(3):531–546.
   PubMed Web of Science ®Google Scholar
• Yin Z, Ker DF, Junkers S, et al. Data-driven prediction of stem cell expansion cultures. In: 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society. Boston, Massachusetts, USA:IEEE; 2011. 3577–3580.
   Google Scholar
• Ker DFE, Weiss LE, Junkers SN, et al. An engineered approach to stem cell culture: automating the decision process for real-time adaptive subculture of stem cells. PLoS One. 2011;6(11):e27672.
   PubMed Web of Science ®Google Scholar
• Phelan K, May KM. Mammalian cell tissue culture techniques. Curr Protoc Mol Biol. 2017;117(1):A.3F.1-A.3F.23.
   PubMedGoogle Scholar
• Freshney RI. Culture of animal cells. Hoboken, NJ, USA: John Wiley & Sons, Inc; 2010.
   Google Scholar
• Phelan MC. Techniques for mammalian cell tissue culture. Curr Protoc Hum Genet. 2006;3:A.3F.1–A.3F.18.
   PubMedGoogle Scholar
• Phelan K, May KM. Basic techniques in mammalian cell tissue culture. Curr Protoc Cell Biol. 2015;2015:1.1.1–1.1.22.
   Google Scholar
• Senger RS, Karim MN. Optimization of fed-batch parameters and harvest time of CHO cell cultures for a glycosylated product with multiple mechanisms of inactivation. Biotechnol Bioeng. 2007;98(2):378–390.
   PubMed Web of Science ®Google Scholar
• Kotidis P, Jedrzejewski P, Sou SN, et al. Model-based optimization of antibody galactosylation in CHO cell culture. Biotechnol Bioeng. 2019;116:1612–1626.
   PubMed Web of Science ®Google Scholar
• ISO International Organization for Standardization. ISO 9001:2015 - Quality management systems — Requirements [Internet]. 2015 [cited 2020 Dec 16]. Available from: https://www.iso.org/standard/62085.html
   Google Scholar
• Heathman TRJ, Glyn VAM, Picken A, et al. Expansion, harvest and cryopreservation of human mesenchymal stem cells in a serum-free microcarrier process. Biotechnol Bioeng. 2015;112(8):1696–1707.
   PubMed Web of Science ®Google Scholar
• Schinzel RT, Ahfeldt T, Lau FH, et al. Efficient culturing and genetic manipulation of human pluripotent stem cells. PLoS One. 2011;6(12):e27495.
   PubMed Web of Science ®Google Scholar
• Shariatzadeh M, Chandra A, Wilson SL, et al. Distributed automated manufacturing of pluripotent stem cell products. Int J Adv Manuf Technol. 2020;106(3–4):1085–1103.
   PubMed Web of Science ®Google Scholar
• Reuveny S, Velez D, Macmillan JD, et al. Factors affecting cell growth and monoclonal antibody production in stirred reactors. J Immunol Methods. 1986;86:53–59.
   PubMed Web of Science ®Google Scholar
• Hunsberger JG, Shupe T, Atala A. An industry-driven roadmap for manufacturing in regenerative medicine. Stem Cells Transl Med. 2018;7(8):564–568.
   PubMed Web of Science ®Google Scholar
• Hourd P, Chandra A, Alvey D, et al. Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products. Regen Med. 2014;9(6):799–815.
   PubMed Web of Science ®Google Scholar
• Andrews PW, Goodfellow PN, Shevinsky LH, et al. Cell‐surface antigens of a clonal human embryonal carcinoma cell line: morphological and antigenic differentiation in culture. Int J Cancer. 1982;29(5):523–531.
   PubMed Web of Science ®Google Scholar
• Tewary M, Shakiba N, Zandstra PW. Stem cell bioengineering: building from stem cell biology. Nat Rev Genet. 2018;19(10):595–614.
   PubMed Web of Science ®Google Scholar
• Cooper S. Distinguishing between linear and exponential cell growth during the division cycle: single-cell studies, cell-culture studies, and the object of cell-cycle research. Theor Biol Med Model. 2006;3(1):10.
   PubMedGoogle Scholar
• Gage BK, Webber TD, Kieffer TJ. Initial cell seeding density influences pancreatic endocrine development during in vitro differentiation of human embryonic stem cells. PLoS One. 2013;8(12):8.
   Web of Science ®Google Scholar
• Jacobs K, Zambelli F, Mertzanidou A, et al. Higher-density culture in human embryonic stem cells results in DNA damage and genome instability. Stem Cell Reports. 2016;6(3):330–341.
   PubMed Web of Science ®Google Scholar
• Kempf H, Olmer R, Haase A, et al. Bulk cell density and Wnt/TGFbeta signalling regulate mesendodermal patterning of human pluripotent stem cells. Nat Commun. 2016;7(1):13602.
   PubMedGoogle Scholar
• Bulusu V, Aulehla A. Metabolic control of cellular differentiation. Dev Cell. 2016;39:286–287.
   PubMed Web of Science ®Google Scholar
• Martano G, Borroni EM, Lopci E, et al. Metabolism of stem and progenitor cells: proper methods to answer specific questions. Front Mol Neurosci. 2019;12:151.
   PubMed Web of Science ®Google Scholar
• Shyh-Chang N, Ng HH. The metabolic programming of stem cells. Genes Dev. 2017;31(4):336–346.
   PubMed Web of Science ®Google Scholar
• Thomson M, Liu SJ, Zou LN, et al. Pluripotency factors in embryonic stem cells regulate differentiation into germ layers. Cell. 2011;145(6):875–889.
   PubMed Web of Science ®Google Scholar
• Wattanapanitch M, Klincumhom N, Potirat P, et al. Dual small-molecule targeting of SMAD signaling stimulates human induced pluripotent stem cells toward neural lineages. PLoS One. 2014;9(9):e106952.
   PubMed Web of Science ®Google Scholar
• Kirkeby A, Nelander J, Parmar M. Generating regionalized neuronal cells from pluripotency, a step-by-step protocol. Front Cell Neurosci. 2013;6:1–4.
   Web of Science ®Google Scholar
• Wilson HK, Canfield SG, Hjortness MK, et al. Exploring the effects of cell seeding density on the differentiation of human pluripotent stem cells to brain microvascular endothelial cells. Fluids Barriers CNS. 2015;12(1):1–12.
   PubMedGoogle Scholar
• Singh SJ, Turner W, Glaser DE, et al. Metabolic shift in density-dependent stem cell differentiation. Cell Commun Signal. 2017;15(1):44.
   PubMedGoogle Scholar
• Horiguchi I, Urabe Y, Kimura K, et al. Effects of glucose, lactate and basic FGF as limiting factors on the expansion of human induced pluripotent stem cells. J Biosci Bioeng. 2018;125:111–115.
   PubMed Web of Science ®Google Scholar
• Palm W, Thompson CB. Nutrient acquisition strategies of mammalian cells. Nature. 2017;546:234–242.
   PubMed Web of Science ®Google Scholar
• O’Brien CM, Mulukutla BC, Mashek DG, et al. Regulation of metabolic homeostasis in cell culture bioprocesses. Trends Biotechnol. 2020;38(10):1113–1127.
   PubMed Web of Science ®Google Scholar
• Wall IB, Davie N. Quality control in cell and tissue engineering. Standardisat Cell Tissue Eng. 2013;148–65.
   Google Scholar
• Coecke S, Balls M, Bowe G, et al. Guidance on good cell culture practice. Cell Technol Cell Prod. 2007;page 313–5.
   Google Scholar
• Knight LA, Cree IA. Quality assurance and good laboratory practice. Methods Mol Biol. 2011;731:115–124. .
   PubMedGoogle Scholar
• NICE. NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma | News and features | News | NICE [Internet]. NICE 2019; //www.nice.org.uk/news/article/nice-recommends-another-revolutionary-car-t-cell-therapy-for-adults-with-lymphoma
   Google Scholar
• Kuehn BM. The promise and challenges of CAR-T gene therapy. J Am Med Assoc. 2017;318(22):2167–2169.
   PubMed Web of Science ®Google Scholar